Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSEY IPSEN	$48.76 -0.2%	$47.22	$28.59 ▼ $51.10	$16.35B	0.46	870 shs	109 shs
SDZNY Sandoz Group	$83.13 -4.0%	$81.35	$45.56 ▼ $94.15	$36.58B	0.56	21,345 shs	27,229 shs
TAK Takeda Pharmaceutical	$16.61 -0.1%	$17.59	$12.99 ▼ $18.90	$52.86B	-0.06	3.04 million shs	2.79 million shs
UCBJY UCB	$137.05 -1.7%	$146.28	$87.17 ▼ $168.76	$51.81B	0.45	43,352 shs	21,257 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSEY IPSEN	0.00%	-0.20%	-0.79%	+8.43%	+71.21%
SDZNY Sandoz Group	0.00%	-3.53%	-0.56%	-3.03%	+85.06%
TAK Takeda Pharmaceutical	0.00%	+0.76%	-6.60%	-10.14%	+21.34%
UCBJY UCB	0.00%	-0.83%	-9.87%	-16.99%	+59.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSEY IPSEN	$48.76 -0.2%	$47.22	$28.59 ▼ $51.10	$16.35B	0.46	870 shs	109 shs
SDZNY Sandoz Group	$83.13 -4.0%	$81.35	$45.56 ▼ $94.15	$36.58B	0.56	21,345 shs	27,229 shs
TAK Takeda Pharmaceutical	$16.61 -0.1%	$17.59	$12.99 ▼ $18.90	$52.86B	-0.06	3.04 million shs	2.79 million shs
UCBJY UCB	$137.05 -1.7%	$146.28	$87.17 ▼ $168.76	$51.81B	0.45	43,352 shs	21,257 shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSEY IPSEN	0.00%	-0.20%	-0.79%	+8.43%	+71.21%
SDZNY Sandoz Group	0.00%	-3.53%	-0.56%	-3.03%	+85.06%
TAK Takeda Pharmaceutical	0.00%	+0.76%	-6.60%	-10.14%	+21.34%
UCBJY UCB	0.00%	-0.83%	-9.87%	-16.99%	+59.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSEY IPSEN	2.00	Hold	N/A	N/A
SDZNY Sandoz Group	3.50	Strong Buy	N/A	N/A
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
UCBJY UCB	3.33	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPSEY, UCBJY, TAK, and SDZNY Analyst Ratings

Date	Company	Brokerage	Action	Rating
5/14/2026	IPSEY IPSEN	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/13/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/5/2026	SDZNY Sandoz Group	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/29/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
4/14/2026	IPSEY IPSEN	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
4/14/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/8/2026	TAK Takeda Pharmaceutical	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/1/2026	SDZNY Sandoz Group	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
3/23/2026	SDZNY Sandoz Group	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
3/3/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
2/26/2026	SDZNY Sandoz Group	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSEY IPSEN	$4.16B	3.93	$5.51 per share	8.85	$14.64 per share	3.33
SDZNY Sandoz Group	$11.09B	3.30	$3.61 per share	23.02	$21.33 per share	3.90
TAK Takeda Pharmaceutical	$4.51T	0.01	$3.18 per share	5.22	$14.39 per share	1.15
UCBJY UCB	$8.76B	5.92	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSEY IPSEN	$501.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	7/30/2026 (Estimated)
SDZNY Sandoz Group	$914M	N/A	N/A	17.92	1.80	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.39	42.59	9.44	N/A	4.31%	11.23%	5.54%	7/30/2026 (Estimated)
UCBJY UCB	$1.76B	N/A	N/A	19.19	1.30	N/A	N/A	N/A	7/30/2026 (Estimated)

Latest IPSEY, UCBJY, TAK, and SDZNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/31/2026	Q4 2025	TAK Takeda Pharmaceutical	N/A	$0.5610	N/A	-$0.0485	N/A	$6.90 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSEY IPSEN	$0.26	0.53%	N/A	N/A	N/A
SDZNY Sandoz Group	$0.61	0.73%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.50	3.01%	-2.41%	128.21%	N/A
UCBJY UCB	$0.52	0.38%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSEY IPSEN	N/A	1.96	1.79
SDZNY Sandoz Group	0.53	1.18	0.77
TAK Takeda Pharmaceutical	0.56	1.19	0.65
UCBJY UCB	0.20	1.38	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSEY IPSEN	N/A
SDZNY Sandoz Group	0.06%
TAK Takeda Pharmaceutical	9.17%
UCBJY UCB	N/A

Insider Ownership

Company	Insider Ownership
IPSEY IPSEN	N/A
SDZNY Sandoz Group	N/A
TAK Takeda Pharmaceutical	0.04%
UCBJY UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSEY IPSEN	5,358	335.26 million	N/A	Not Optionable
SDZNY Sandoz Group	23,567	440.00 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
UCBJY UCB	10,117	378.04 million	N/A	Not Optionable

IPSEY, UCBJY, TAK, and SDZNY Headlines

Recent News About These Companies

UCB ADR Stock Price History

May 16 at 8:56 AM | investing.com

UCB (OTCMKTS:UCBJY) Shares Gap Down - Here's Why

April 29, 2026 | marketbeat.com

UCB (OTCMKTS:UCBJY) Stock Price Down 4.3% - Time to Sell?

April 21, 2026 | marketbeat.com

Belgian pharma UCB to buy US.-based Neurona for up to $1.15B

April 17, 2026 | msn.com

UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know

April 15, 2026 | zacks.com

Belgium's UCB in autoimmune drug deal with Antengene

March 3, 2026 | reuters.com

Berenberg maintains UCB SA - depositary receipt (UCBJY) buy recommendation

December 16, 2025 | msn.com

Recent Price Trend in UCB (UCBJY) is Your Friend, Here's Why

September 25, 2025 | zacks.com

UCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why

September 9, 2025 | zacks.com

All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy

August 22, 2025 | msn.com

Here's Why Momentum in UCB (UCBJY) Should Keep going

August 6, 2025 | msn.com

UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 16, 2025 | msn.com

UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact

July 16, 2025 | tipranks.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price ... - Nasdaq

July 11, 2025 | nasdaq.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price Strength

July 9, 2025 | msn.com

TD Cowen maintains UCB stock Buy rating, EUR250 target

March 27, 2025 | uk.investing.com

UCB SA (UCBJY)

February 2, 2025 | finance.yahoo.com

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

January 17, 2025 | finance.yahoo.com

UCB (OTC:UCBJY) Stock Quotes, Forecast and News Summary

November 22, 2024 | benzinga.com

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

November 20, 2024 | benzinga.com

Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

November 19, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPSEY, UCBJY, TAK, and SDZNY Company Descriptions

IPSEN OTCMKTS:IPSEY

$48.76 -0.10 (-0.20%)

As of 05/15/2026 11:18 AM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Sandoz Group OTCMKTS:SDZNY

$83.13 -3.49 (-4.03%)

As of 05/15/2026 03:55 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical NYSE:TAK

$16.61 -0.02 (-0.11%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$16.63 +0.02 (+0.14%)

As of 05/15/2026 05:03 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB OTCMKTS:UCBJY

$137.05 -2.34 (-1.68%)

As of 05/15/2026 03:50 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPSEY, UCBJY, TAK, and SDZNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPSEY, UCBJY, TAK, and SDZNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPSEY, UCBJY, TAK, and SDZNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IPSEY, UCBJY, TAK, and SDZNY Company Descriptions

IPSEN OTCMKTS:IPSEY

Sandoz Group OTCMKTS:SDZNY

Takeda Pharmaceutical NYSE:TAK

UCB OTCMKTS:UCBJY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPSEY, UCBJY, TAK, and SDZNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPSEY, UCBJY, TAK, and SDZNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPSEY, UCBJY, TAK, and SDZNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IPSEY, UCBJY, TAK, and SDZNY Company Descriptions

IPSEN OTCMKTS:IPSEY

Sandoz Group OTCMKTS:SDZNY

Takeda Pharmaceutical NYSE:TAK

UCB OTCMKTS:UCBJY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools